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Humane Society International’s Global Campaign to End
Animal Testing
Troy Seidlea
Research & Toxicology Department, Humane Society International, Toronto, ON, Canada
Summary — The Research & Toxicology Department of Humane Society International (HSI) operates a multifaceted and science-driven global programme aimed at ending the use of animals in toxicity testing and
research. The key strategic objectives include: a) ending cosmetics animal testing worldwide, via the multinational Be Cruelty-Free campaign; b) achieving near-term reductions in animal testing requirements
through revision of product sector regulations; and c) advancing humane science by exposing failing animal models of human disease and shifting science funding toward human biology-based research and testing tools fit for the 21st century. HSI was instrumental in ensuring the implementation of the March 2013
European sales ban for newly animal-tested cosmetics, in achieving the June 2013 cosmetics animal testing ban in India as well as major cosmetics regulatory policy shifts in China and South Korea, and in securing precedent-setting reductions in in vivo data requirements for pesticides in the EU through the revision
of biocides and plant protection product regulations, among others. HSI is currently working to export
these life-saving measures to more than a dozen industrial and emerging economies.
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Introduction
Humane Society International (HSI), and its affiliates, together constitute one of the world’s largest
and most effective forces for animal protection.
HSI is widely respected as an authority on animal
research and testing issues, and is frequently
called upon by governments, corporations and
other official bodies for its advice and expert opinion. Its team of scientists, policy experts, campaign
professionals, investigators and supporters spans
the globe, acting as a voice for humane and
human-relevant testing and research that moves
beyond outdated animal models by using the most
advanced tools that 21st century science has to
offer.

HSI Strategy and Accomplishments
Be Cruelty-Free: Ending cosmetics animal
testing worldwide
HSI played a leading role in driving European
institutions to follow through on their commitment
to ban the sale of newly animal-tested cosmetics,

aThe

which became effective on 11 March 2013. Years of
high-level political negotiations were coupled with
high-profile public campaigning — including
recruitment of top celebrity supporters such as Sir
Paul McCartney, Leona Lewis, Ricky Gervais and
many others, and a corporate partnership with
Lush cosmetics, through which hundreds of thousands of petition signatures were collected in mere
weeks — to achieve the celebrated victory: a
Europe free from cosmetics animal cruelty. Yet so
long as powerful emerging markets such as China
continue to require animal testing, not only for
new cosmetic ingredients, but also for each new
product formulation (1), HSI’s efforts could not
remain limited to Europe.
Be Cruelty-Free was born from the recognition
that the global nature of the cosmetics industry, coupled with differing regional regulatory requirements
(2), necessitated a coordinated, multinational strategy, if a worldwide end to animal testing for cosmetics was to be achieved. In April 2012, HSI and its
affiliates, in partnership with Lush and animal protection groups in Australia, Brazil, Canada, India,
Korea, New Zealand, Russia and the USA, launched
Be Cruelty-Free, with the goal of making cruelty-free
cosmetics the global mainstream by replicating the
European animal testing and sales bans across all

author was a member of the 2012 Lush Prize judging panel.
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key global cosmetics markets. A global online pledge
was launched at hsi.org/becrueltyfree and in more
than 700 Lush shops in 48 countries, to educate consumers and provide them with an avenue to support
the campaign. Be Cruelty-Free has since expanded
also into China, Japan and Taiwan, for a total of 12
concurrent regional campaigns (Figure 1).
A partial list of Be Cruelty-Free’s achievements
to date include the following:
— In India, being instrumental in convincing policymakers to delete the last remaining animal
tests from the country’s cosmetics standard
(3), thereby effectively banning cosmetics testing involving animals. Today, HSI–India is
holding top-level meetings with Government
officials to achieve an extension of the ban to
prohibit also the sale of cosmetics that have
been subject to new animal testing in other
parts of the world.
— In Brazil, influencing the revision of national
cosmetics safety assessment guidelines, which
were updated following an HSI workshop in
December 2012, and now provide for acceptance
of all Three Rs test guidelines promulgated by
the Organisation for Economic Co-operation
and Development (OECD; 4). In September
2013, HSI filed a regulatory proposal with
Brazil’s Conselho Nacional de Controle de
Experimentação Animal (CONCEA) calling for
a national cosmetics animal testing ban, with
the backing of more than 150 Brazilian federal
parliamentarians.
— In China, HSI and the Humane Society of the
United States (HSUS) have awarded an
$80,000 grant to the Institute for In Vitro
Sciences (IIVS) to provide hands-on training to
government regulators, and academia and
industry scientists, on the use and interpretation of non-animal OECD test guideline methods. In previous years, HSI has co-funded
similar IIVS training courses for Brazilian and
Russian stakeholders. Since the launch of Be
Cruelty-Free in China, the China Food and
Drug Administration has announced the first
revision of the country’s cosmetics framework
regulation in 20 years.
— In South Korea, intensive political, regulatory
and corporate engagement prompted the
Ministry of Food and Drug Safety to announce
a significant policy shift to formally recognise
non-animal test results for assuring the safety
of sunscreens, anti-wrinkle creams and other
‘functional’ cosmetics. Additionally, the government has committed to invest 166 billion Won
(approx. $145 million) to establish Korea’s first
Centre for Alternatives to Animal Testing.
— In New Zealand, HSI delivered a similar submission to the Parliament, as it reviews the
country’s Animal Welfare Act. HSI and our NZ
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cam paign partner have also launched a
national advertising campaign calling for Kiwi
Prime Minister John Key to ‘hop to it’ and ban
animal testing for cosmetics (Figure 2).
HSI and its partners are also working to influence
new and revised laws and regulations governing
the trade and testing of chemicals (similar to the
Europe’s Registration, Evaluation, Authorisation
and Restriction of Chemicals [REACH] system,
discussed further below) to prevent the creation of
loopholes that would allow, or even require, new
animal testing for cosmetic raw ingredients. In
many parts of the world, Be Cruelty-Free has put
the animal testing issue on the public policy
agenda for the very first time. Yet, from the
Americas to Asia and Oceania, opinion polls
funded by HSI and its partners have revealed
unprecedented levels of public support for nationwide bans on cosmetics animal testing (5), and Be
Cruelty-Free is helping to drive public policy discussions in Brazil, China, New Zealand, South
Korea and beyond, with first-of-their-kind legislative proposals arguing the case for cosmetics animal testing bans.

Revision of product sector regulatory data
requirements
The efficient uptake of ‘Three Rs best practices’, to
achieve practical, near-term reduction in animal
use in product sectors (pesticides, industrial chemicals, medicinal products, etc), is hampered by
complex and highly regionalised regulatory frameworks and data requirements. Progress requires a
sector-specific and region-specific approach, and
often upwards of two years of detailed scientific
negotiations with regulators, industry and other
stakeholders are necessary to achieve a revised
regulation that fulfils the objectives of: a) adopting
all available OECD Three Rs test guidelines and
guidance; b) providing flexibility to enable the use
of the most efficient testing strategies to reduce
animal use to the greatest possible extent without
compromising human health or environmental
protection; and c) laying the groundwork for a
transition toward a future adverse outcome pathway (AOP)-based testing and risk assessment paradigm (6).

Pesticides
Today, testing to meet regulatory requirements for
a new pesticide active ingredient can consume
more than 10,000 rodents, rabbits, fish, birds, dogs
and other animals, in dozens of separate toxicity
and ecotoxicity studies. Animal testing is also carried out on all finished products, and is often

Figure 1: Humane Society International’s global Animal Testing Campaign
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Figure 2: Be Cruelty-Free national advertising campaign in New Zealand

required for the re-registration of existing active
ingredients. Overt redundancies abound, including, for some endpoints, the requirement for the
same study via multiple exposure routes (e.g.
acute, subacute and subchronic testing via oral
and/or dermal and/or inhalation routes), or in more
than one species (e.g. subchronic and chronic testing in rodents and dogs, prenatal developmental
toxicity in rodents and rabbits, carcinogenicity in
rats and mice, fish acute studies in two or more
species, etc).

Between 2010 and 2013, HSI and its partners
undertook to influence technical and political negotiations around the scheduled revision of European
directives for plant protection and biocidal products (i.e. agricultural and non-agricultural pesticides, respectively). Working from regulatory
proposals drafted by the European Commission,
HSI identified more than 100 opportunities to
revise toxicological data requirements for biocides,
in order to remove redundancies and incorporate
new OECD Three Rs guideline methods and other

Humane Society International’s global campaign

innovative testing strategies. In the case of acute
toxicity, HSI collaborated with the European
Centre for the Validation of Alternative Methods
(ECVAM) to carry out a new data analysis to objectively examine the regulatory value of testing via
multiple exposure routes (7).
The political process involved multiple rounds of
negotiations with Commission scientists, Parliamentary rapporteurs and Member State regulators. Ultimately, more than 80 amendments put
forward by HSI were adopted in the new EU
Biocidal Products Regulation (8), including:
— deletion of the dog chronic toxicity study;
— uptake of the new OECD Extended One-generation Reproductive Toxicity Study;
— downgrading several second route/species study
types to conditional requirements;
— a requirement to consider combining two or
more endpoints within the framework of a single repeated-dose toxicity study (e.g. the addition of neuro/immuno endpoints and/or the
presence of micronuclei for genotoxicity assessment); and
— broad provision for ‘classification by calculation’
for formulations and finished products.
These and other measures, when taken together,
represent possibly the largest one-time reduction
in in vivo data requirements in a regulated product
sector, and are the bases on which HSI was
awarded the 2012 Lush Prize for lobbying (lushprize.org). A number of similar measures have also
been taken up in new EU regulations setting out
data requirements for plant protection products (9,
10). Since achieving these regulatory precedents in
the EU, HSI has begun active outreach to pesticide
regulators in Canada, India, Brazil and the USA,
with an eye to extending these Three Rs best practices globally, and already some progress has been
achieved (11).

Chemicals
In addition to advocating global uptake of Three Rs
best practices within the pesticide sector, HSI is
also actively pressing the EU to revise data
requirements under the REACH chemical regulations (12). Millions of animals could be spared suffering and death, if EU chemical regulators would
simply accept the same Three Rs best practices
that have already been taken up by their pesticide
regulatory counterparts, for the tens of thousands
of substances that fall within the scope of REACH.
Not only is this the responsible and humane
option, it is also a legal requirement under REACH
that animal testing be carried out only as a last
resort (Article 25.1), and that data requirements
be updated “as soon as possible” and “with a view
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to reducing testing on vertebrate animals” (Article
13.2). Yet, despite this mandate, and that more
than 18 months have passed since HSI presented
its proposal to update REACH data requirements,
meaningful action on the part of the European
Commission remains conspicuously absent.
European progress in this area is also consequential for other countries that have chosen to emulate
REACH as a model for their own domestic chemical regulations (e.g. China REACH, and K-REACH
in South Korea). HSI and its regional partners are
actively working to influence new and revised
chemical regulations, particularly in the
Asia–Pacific region, to ensure that contemporary
Three Rs best practices are taken up in lieu of
alignment with the now outdated EU REACH regulations.

Advancing humane science

AXLR8 and the Human Toxicology Project
The view that conventional animal models of
human safety and efficacy are time-intensive and
resource-intensive, restrictive in the number of
substances that can be tested, of limited use in providing mechanistic understanding, and of even
more limited relevance to human biology, has gone
from being dismissed as anti-vivisectionist rhetoric, to being embraced as a compelling driver for a
fundamental paradigm shift in toxicology (13). The
US National Academy of Sciences 2007 report (14)
has not only inspired a number of regional and
multinational research efforts aimed at advancing
‘21st century toxicology’ — from the US interagency Tox21 collaboration (epa.gov/ncct/tox21), to
the European SEURAT-1 project (seurat-1.eu) and
the OECD global initiative to map AOPs
(bit.ly/1hFUYl6) — it has also shifted the discussion from whether animal testing can be replaced,
to how quickly this goal can be achieved (15).
Leading universities, research institutes and
companies have joined HSI under the EU 7th
Framework project, AXLR8 (axlr8.eu), to develop a
roadmap to guide 21st century toxicology-related
EU research investment under the forthcoming
funding programme, Horizon 2020 (16). In addition, through the Human Toxicology Project
Consortium (htpconsortium.org), HSI, HSUS and
corporate partners are working hand-in-hand on a
global basis, to dramatically increase public and
private research funding in this important area
(Figure 1). HSI also serves on a number of governmental expert and stakeholder advisory bodies,
including at European and OECD levels, where we
contribute to high-level discussions regarding
processes for the validation and regulatory acceptance of novel testing tools. HSI is honoured also to
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have two of its scientists serving as judges for the
Lush Prize, to help promote and award tangible
progress toward animal replacement.

Disease models in biomedical research
In contrast to the relatively rapid shift under way
in toxicology, the inertia in the wider biomedical
research community — which accounts for more
than 80% of all animal use for scientific purposes
— is more pronounced. Intolerance persists of
questions, or criticisms, regarding the validity and
value of animal models of human disease, despite
a scant and painstakingly slow rate of progress in
crucial disease areas and an ever-growing body of
published evidence pointing to the need for a shift
in research paradigm (17–22). As noted by the former US National Institutes of Health director,
Elias Zerhouni:
“We have moved away from studying human disease in humans… We all drank the Kool-Aid on
that one, me included… The problem is that it hasn’t
worked, and it’s time we stopped dancing around
the problem… We need to refocus and adapt new
methodologies for use in humans to understand
disease biology in humans.” (23)
In the interests of stimulating further constructive
debate within the biomedical research community,
HSI and HSUS scientists have begun contributing
scholarly reviews in several disease areas, including asthma (24), Alzheimer’s disease, Parkinson’s
disease, and Amyotrophic Lateral Sclerosis (K.
Willett, personal communication, 01.11.13). Recently, HSI launched a grant programme to sponsor
reviews and publications by independent academic
scientists that critically examine animal models in
a particular disease area, and propose a forwardlooking scientific ‘roadmap’ for the disease area
based on 21st century human biology-based (nonanimal) tools. Interventions from HSI in political
negotiations for Horizon 2020 have already
achieved new directional language to better-focus
future EU health research funding on human-relevant approaches (in lieu of more genetically-modified mice), with emphasis on AOP discovery and
bioinformatics, expanded development of human
biology-based cellular and computational tools,
and funding for new research infrastructures such
as high-throughput in vitro screening and supercomputing capacity. HSI will provide funding for
its disease model grant recipients to present their
publications at key scientific conferences worldwide, and will organise high-level briefings for
national public and private research funding bodies, with an eye to shifting resources away from
failing models in the interests of more-humane
investments and better returns for human health.
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Conclusions
Investment in the science needed to replace the
use of animals in testing and research is much
more than a political objective driven by ethical
considerations; it is an opportunity to improve our
fundamental understanding of human biology as a
means of achieving optimal health and being able
to effectively treat — and ideally prevent — disease. In the interim, incremental, yet significant,
reductions in animal use can be achieved through
more-robust application of established Three Rs
best practices across regulated product sectors
globally, laying the groundwork for a more substantial methodological shift over the longer-term.
In emerging economies, an initial focus on cosmetics provides an effective gateway through which to
inform and engage the public and policymakers
and put the animal testing issue on the government agenda.
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